HOME >> MEDICINE >> NEWS
Studies indicate medication can be an effective therapy for smoking cessation

The drug varenicline shows effectiveness in helping smokers quit and abstain from smoking when compared to placebo and the smoking cessation medication bupropion, according to three studies in the July 5 issue of JAMA.

Although nearly 41 percent of smokers try to quit smoking each year, relapse is common, and only about 10 percent achieve and maintain abstinence. The negative effects of nicotine withdrawal account, in part, for low success rates, according to background information in the article. Approved pharmacotherapies to treat nicotine dependence (e.g., nicotine replacement therapy and bupropion) have had important, but moderate efficacy, with reported rates of quitting generally twice those of placebo. Additional and more effective therapies are needed.

David Gonzales, Ph.D., of Oregon Health & Science University, Portland, and colleagues with the Varenicline Phase 3 Study Group evaluated the efficacy of varenicline compared with placebo and sustained-release (SR) bupropion in generally healthy adult smokers. Varenicline is a non-nicotine drug that is thought to be beneficial for smoking cessation by stimulating the release of the chemical dopamine in the brain to reduce craving and withdrawal while simultaneously blocking the reinforcing effects of smoked nicotine. Most other smoking cessation pharmacotherapies are nicotine replacement products.

Participants in the study were 1,025 smokers (10 cigarettes or more per day) with fewer than 3 months of smoking abstinence in the past year. The randomized, double-blind, phase 3 clinical trial was conducted at 19 U.S. centers from June 2003 to April 2005. Participants were randomly assigned to receive brief counseling plus either varenicline twice per day (n = 352), bupropion SR twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up.

The carbon monoxideconfirmed 4-week continuous abstinence rate for weeks 9 th
'"/>

Contact: Tamara Hargens
503-494-8231
JAMA and Archives Journals
4-Jul-2006


Page: 1 2 3 4 5 6 7

Related medicine news :

1. Studies show antidepressants not linked to birth defects
2. Studies show role of age, gender, race and weight on cancer risk and treatment
3. Studies suggest investigational agent reduces disease activity in MS
4. Studies highlight advances in diagnosis, medical therapy
5. Studies highlight real world use, safety of drug-eluting stents
6. Studies led by Rhode Island Hospital confirm safety and efficacy
7. Studies identify food sources of disease and drug resistance
8. Studies provide new evidence on risks associated with Cox-2 inhibitors and NSAIDs
9. Studies highlight need to monitor heart function in breast cancer patients
10. Studies examine physician disclosure of medical errors
11. Studies evaluating health effects of dental amalgam fillings in children confirm safety

Post Your Comments:
(Date:4/23/2014)... Ritalin, may prevent the depletion of self-control, according to ... of the Association for Psychological Science. , Self-control can ... to focus attention on a boring textbook are hard ... for this difficulty: Exerting self-control for a long period ... on subsequent tasks. , "It is as if self-control ...
(Date:4/22/2014)... New Jersey Institute of Technology (NJIT) today to ... launch of the New Jersey Innovation Institute (NJII), ... for business innovation through the leveraging of industry, ... Senator Cory Booker, Panasonic Corp. of North America ... Governor Kim Guadagno, New Jersey Secretary of Higher ...
(Date:4/22/2014)... DALLAS April 22, 2014 Researchers at UT ... people suffering from depression . , A ... major mechanism by which ghrelin (a hormone with natural ... identified a potentially powerful new treatment for depression in ... , The study, published online in April,s ...
(Date:4/22/2014)... Washington, DC (April 22, 2014) The International ... May 22-26 in Seattle, Washington. The theme of ... life" means in a networked and digital society. ... and attended by over 2,200 Communication scholars representing ... largest scholarly international communication conference in the world. ...
(Date:4/22/2014)... 2014. The latest scientific advances and emerging therapies in ... the main annual meeting of the Heart Failure Association ... will also hear breaking news on acute heart failure ... which is part of the main congress. , The ... at the Megaron Athens International Conference Centre (MAICC). The ...
Breaking Medicine News(10 mins):Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2Health News:The world's largest heart failure congress 2Health News:The world's largest heart failure congress 3
(Date:1/14/2014)... 14, 2014 NineSigma , Inc., the leading ... Innovation Leadership Summit , May 14-16, 2014 at the ... Ohio . This is the ... to breakthrough achievements through open innovation. Participants will learn ...
(Date:1/14/2014)... York , January 14, 2014 ... System Transfer Devices (CSTD) for hazardous drugs, today announced that ... the fourth straight year.   Equashield,s ... pharmacy technicians, pharmacists, nurses and other medical professionals ...
(Date:1/14/2014)... 2014 Spark Therapeutics , a late-stage gene therapy company, ... program, a Phase 3 study for inherited retinal dystrophies caused by ... D. Marrazzo , is presenting this and other corporate updates today, ... San Francisco . Marrazzo said Spark was able to achieve ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
Cached News: